Use Of Carbamate Compound In Order To Preventatively Treat Headaches

• US 20190216780A1
• Filed: 05/18/2017
• Published: 07/18/2019
• Est. Priority Date: 05/19/2016
• Status: Active Grant

• Current Assignee: SK Biopharmaceuticals Co., Ltd. (SK Inc.)
• Original Assignee: SK Biopharmaceuticals Co., Ltd. (SK Inc.)
• Inventors: SHIN, Hye Won, PARK, Yoon Kyung
• Granted Patent: US 10,456,376 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• CPC Class Codes: A61K 9/00 Medicinal preparations characterised by special physical form nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12
• CPC Class Codes: A61K 9/28 Dragees; Coated pills or tablets , e.g. with film or compression coating A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209
• CPC Class Codes: A61P 25/06 Antimigraine agents

Abstract

The present invention relates to a pharmaceutical composition for preventatively treating headaches, containing: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt, solvent or hydrate thereof; and a pharmaceutically acceptable carrier. According to the present invention, the pharmaceutical composition can effectively prevent a headache, more specifically, headaches caused by cortical spreading depression, and particularly, chronic headaches including migraines.

Claims

1-22. -22. (canceled)

23. A method for prophylactically treating headaches in a subject, comprising:

administering a therapeutically effective amount of a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof to the subject;

24. The method according to claim 23, wherein R₁ and R₂ are each independently selected from the group consisting of hydrogen, halogen and C₁-C₈ alkyl.

25. The method according to claim 23, wherein the carbamate compound of Formula 1 is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester of Formula 2:

26. The method according to claim 23, wherein the headache is headache associated with cortical spreading depression (CSD).

27. The method according to claim 23, wherein the headache is chronic headache.

28. The method according to claim 23, wherein the headache is migraine.

29. The method according to claim 28, wherein the migraine is migraine with aura.

30. The method according to claim 23, wherein the subject is a mammal.

31. The method according to claim 30, wherein the mammal is a human.

32. The method according to claim 23, wherein the therapeutically effective amount of the carbamate compound of Formula 1 is 10 to 500 mg based on once-daily administration.

41. The method according to claim 23, wherein the carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof is administered orally, parenterally, intravenously, intramuscularly, subcutaneously or rectally.

33-40. -40. (canceled)